Delivery Order SPE2DB24D2010-SPE2DB25FAAHY
- Not listed
- The Defense Logistics Agency awarded a $5,590.59 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Orencia 125 mg/ml syringes. This competitively awarded, firm fixed-price contract is not set-aside and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. Performance will be executed from the contractor's location in...
- The Defense Logistics Agency awarded a delivery order valued at $3,675.77 to AmerisourceBergen Drug Corp for Orencia 125 mg/ml syringes. This contract, issued on June 18, 2025, with an ultimate completion date of June 20, 2025, represents a firm fixed-price procurement with no set-aside designation. The award was made competitively and reflects AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and healthcare systems. The place of performance is the company's...
- The Defense Logistics Agency awarded a $11,893.95 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Orencia 125 mg/ml syringes. This non-set-aside competitive award is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Orencia 125 mg/mL syringes, valued at $3,701.46. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Orencia 125 mg/mL syringes valued at $9,779.31. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $49,728.04 to AmerisourceBergen Drug Corp for the supply of Orencia 125 mg/mL syringes. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of May 19, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $10,890.11 on June 16, 2025, for the supply of Orencia 125 mg/ml syringes. This firm fixed-price delivery order, which is due for completion on June 17, 2025, was competitively awarded without set-aside designation to support the Medical Supply Chain, a division of the Defense Logistics Agency under the Department of Defense. The award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $4,760.13 to AmerisourceBergen Drug Corp for the supply of Orencia 125 mg/mL syringes. The contract, executed on July 25, 2025, with an ultimate completion date of July 28, 2025, is structured as a firm fixed price delivery order with no set-aside designation. Performance will be conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Orencia 125 mg/mL syringes valued at $7,796.46. This non-competitive delivery order is issued under a firm fixed price structure with a completion date of August 28, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued against AmerisourceBergen's Indefinite Delivery...
- The Defense Logistics Agency awarded a $10,711.89 delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Orencia 125 mg/ml syringes. The contract carries a firm fixed price structure with no set-aside designation, reflecting competitive procurement procedures. The award is classified as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FAAHYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $3,570.63 on July 14, 2025, for the supply of Orencia 125 mg/ml syringes. This firm fixed price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its operations as one of the nation's largest pharmaceutical distributors. AmerisourceBergen Drug Corp serves as a critical vendor within the federal medical supply chain, providing a comprehensive portfolio of brand-name and generic pharmaceuticals, vaccines, and specialized medical supplies to support military and veteran healthcare systems. The company's selection through open competition for this delivery order reflects its demonstrated capability to fulfill federal procurement requirements. Orencia, a biologic immunosuppressant used primarily for rheumatoid arthritis treatment, represents one of the specialized pharmaceutical products within the company's extensive federal contract portfolio. The contract has an ultimate completion date of July 15, 2025.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 7/14/25 |